Approval · Notice of Compliance 3477 · 2003
BIPREL: Notice of Compliance 3477
Issued January 31, 2003
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 3477
- Date
- January 31, 2003
- Company
- Servier Canada Inc.Laval, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Update to the indications section of the product monograph: deleted perindopril should normally be used in those patients in whom treatment with a diuretic or beta-blocker was found to be ineffective or has been associated with unacceptable adverse effects. to be consistent with the product monograph for coversyl
- Therapeutic class
- Angiotensin converting enzyme inhibitor, diuretic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| BIPREL | Not yet assigned | — |
Medicinal ingredients
- PERINDOPRIL ERBUMINE 4 MG per TAB
- INDAPAMIDE 1.25 MG per TAB